PRESS RELEASE published on 09/24/2024 at 14:00, 1 year 7 months ago Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) Lonza and Vertex sign a long-term commercial supply agreement for CASGEVY® cell therapy based on CRISPR/Cas9 gene-editing technology. Lonza to manufacture at Geleen, NL facility approved by FDA, EMA, and MHRA Lonza Cell Therapy Vertex CASGEVY® CRISPR/Cas9
BRIEF published on 08/28/2024 at 18:36, 1 year 8 months ago Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds Lonza EUR 1.2 Billion Corporate Financing Dual-Tranche Bonds Luxembourg Listing
BRIEF published on 08/28/2024 at 18:36, 1 year 8 months ago Lonza fixe le prix d'une émission d'obligations à deux tranches de 1,2 milliard d'euros Lonza Financement Des Entreprises Obligations À Double Tranche 1,2 Milliard D'euros Cotation Au Luxembourg
PRESS RELEASE published on 08/28/2024 at 18:31, 1 year 8 months ago Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds Lonza Group AG's wholly-owned Lonza Finance International NV prices dual-tranche EUR 1.2 billion straight bonds with 3.25% and 3.50% coupons for six and ten years respectively. Bonds to be listed on Luxembourg Stock Exchange for general corporate purposes Lonza Group AG Listing EUR 1.2 Billion Luxembourg Stock Exchange Straight Bonds
BRIEF published on 07/25/2024 at 07:05, 1 year 9 months ago Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members Pharmaceutical Industry Lonza Board Nominations Juan Andres Eric Drapé
BRIEF published on 07/25/2024 at 07:05, 1 year 9 months ago Lonza nomme Juan Andres et Eric Drapé comme membres indépendants du conseil d'administration Lonza Industrie Pharmaceutique Nominations Au Conseil D'administration Juan Andres Eric Drapé
PRESS RELEASE published on 07/25/2024 at 07:00, 1 year 9 months ago Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members Lonza nominates Juan Andres and Eric Drapé as independent board members to enhance governance and expertise. The nominees bring decades of leadership in the pharmaceutical industry Pharmaceutical Industry Lonza Juan Andres Eric Drapé Independent Board Members
BRIEF published on 07/25/2024 at 07:00, 1 year 9 months ago Lonza Group H1 2024 Performance on Track: Sales Increase 1.8% CER, CORE EBITDA Margin at 29.2% Financial Performance Sales Growth Lonza Group H1 2024 Results CORE EBITDA
BRIEF published on 07/25/2024 at 07:00, 1 year 9 months ago Performance du groupe Lonza au premier semestre 2024 en bonne voie : augmentation des ventes de 1,8 % TCC, marge d'EBITDA CORE à 29,2 % Performance Financière Résultats Du Premier Semestre 2024 La Croissance Des Ventes Groupe Lonza EBITDA DE BASE
PRESS RELEASE published on 07/25/2024 at 06:55, 1 year 9 months ago Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin Lonza Group H1 2024 performance on track: 1.8% sales increase, 29.2% CORE EBITDA margin. Full-Year Outlook confirmed CORE EBITDA Margin Sales Increase Full-year Outlook Lonza Group H1 2024 Performance
Published on 05/16/2026 at 01:15, 5 hours 38 minutes ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 6 hours 53 minutes ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 7 hours 43 minutes ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 7 hours 53 minutes ago Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Published on 05/15/2026 at 20:10, 10 hours 43 minutes ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 12 hours 42 minutes ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 17:33, 13 hours 19 minutes ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 05/15/2026 at 15:08, 15 hours 45 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 15 hours 53 minutes ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 20 hours 43 minutes ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 1 day 21 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 2 days 12 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES